Ampio Pharmaceuticals announces funding transaction of $25 million Ampio Pharmaceuticals, Inc. today announced a financing purchase that will offer $25 million in gross proceeds to the Company read more . The Company has entered right into a definitive agreement with a limited number of purchasers, mainly institutional investors, in connection with the registered direct placement of common stock of the business, where the investors have decided to purchase an aggregate of 4,600,319 shares of common stock of the business pursuant to the Company's effective registration statement at an supplying cost of $5.50 per share, for a complete of $25 million of gross proceeds.

The most typical adverse events were nasopharyngitis, higher respiratory tract infection, influenza and back discomfort. Harper, M.D., executive vice president of Advancement and Research at Amgen. Information on the DESCARTES study results will be submitted to a future medical conference and for publication. Based on the Centers for Disease Avoidance and Control, more than 71 million American adults possess high LDL-C.. Amgen reports that Phase 3 DESCARTES research for raised chlesterol meets primary endpoint Amgen today announced that the Phase 3 DESCARTES study evaluating the long-term 52-week protection and efficacy of evolocumab for the treating raised chlesterol met its primary endpoint of % decrease from baseline in low-density lipoprotein cholesterol at week 52. The mean % reduction in LDL-C, or poor cholesterol, was in keeping with the results observed in the 52-week evaluation of the Phase 2 OSLER study.